Finance

Lists
GIS:FRA
Gilead Sciences, Inc
€130,52
+1,78%
(+2,28) 1D
8 ຕ.ລ., 22 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
€130,86
High
€131,76
Low
€129,10
Mkt. cap
182,40 ຕື້
Avg. vol.
399,00
Volume
450,00
52-wk high
€134,58
52-wk low
€97,05
No. of employees
17 ພັນ
Open
€130,86
High
€131,76
Low
€129,10
Mkt. cap
182,40 ຕື້
Avg. vol.
399,00
Volume
450,00
52-wk high
€134,58
52-wk low
€97,05
No. of employees
17 ພັນ
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
2 ຊົ່ວໂມງກ່ອນ
Gilead Sciences stock after-hours at EUR 131.08: minus 0.06 percent
Yahoo! Finance Canada
Yahoo! Finance Canada
·
5 ຊົ່ວໂມງກ່ອນ
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
AD HOC NEWS
AD HOC NEWS
·
5 ຊົ່ວໂມງກ່ອນ
Gilead Sciences stock costs EUR 130.59, volume 2,080,114 shares
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 ພັນ
Founded22 ມິ.ຖ. 1987
HeadquartersFoster City, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
7,77 ຕື້
7,92 ຕື້
6,96 ຕື້
7,80 ຕື້
Cost of goods sold
1,57 ຕື້
1,62 ຕື້
1,44 ຕື້
1,58 ຕື້
Cost of revenue
1,57 ຕື້
1,62 ຕື້
1,44 ຕື້
1,58 ຕື້
Research and development expenses
1,33 ຕື້
1,57 ຕື້
1,36 ຕື້
1,69 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,35 ຕື້
1,78 ຕື້
1,43 ຕື້
1,91 ຕື້
Operating expense
2,69 ຕື້
3,34 ຕື້
2,78 ຕື້
3,60 ຕື້
Total operating expenses
4,26 ຕື້
4,96 ຕື້
4,23 ຕື້
5,18 ຕື້
Operating income
3,51 ຕື້
2,96 ຕື້
2,73 ຕື້
2,63 ຕື້
Other non operating income
-23,00 ລ້ານ
51,00 ລ້ານ
-8,00 ລ້ານ
-
EBT including unusual items
3,64 ຕື້
2,08 ຕື້
2,58 ຕື້
-10,25 ຕື້
EBT excluding unusual items
3,34 ຕື້
2,80 ຕື້
2,59 ຕື້
2,42 ຕື້
Income tax expense
589,00 ລ້ານ
-105,00 ລ້ານ
559,00 ລ້ານ
242,00 ລ້ານ
Effective tax rate
16,18%
-5,05%
21,67%
-2,36%
Other operating expenses
-
-
-
-
Net income
3,05 ຕື້
2,18 ຕື້
2,02 ຕື້
-10,50 ຕື້
Net profit margin
39,28%
27,55%
29,04%
-134,51%
Earnings per share
2,47
1,86
2,03
-6,75
Interest and investment income
88,00 ລ້ານ
95,00 ລ້ານ
95,00 ລ້ານ
45,00 ລ້ານ
Interest expense
-256,00 ລ້ານ
-255,00 ລ້ານ
-240,00 ລ້ານ
-247,00 ລ້ານ
Net interest expenses
-168,00 ລ້ານ
-160,00 ລ້ານ
-145,00 ລ້ານ
-202,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
4,20 ຕື້
3,65 ຕື້
3,42 ຕື້
3,33 ຕື້
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google